Dual oxidase 1: A predictive tool for the prognosis of hepatocellular carcinoma patients

Oncology Reports

Volumn 35, Issue 6, 2016, Pages 3198-3208

  Chen, Shengsen ^a   Ling, Qingxia ^a   Yu, Kangkang ^a   Huang, Chong ^a   Li, Ning ^a   Zheng, Jianming ^a   Bao, Suxia ^a   Cheng, Qi ^a   Zhu, Mengqi ^a   Chen, Mingquan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Biomarker; Dual oxidase 1; Hepatocellular carcinoma; Prognosis; Risk scoring system

Indexed keywords

MESSENGER RNA; PROTEIN DUOX1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; DUOX1 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SURVIVAL PREDICTION; VERY ELDERLY; ENZYMOLOGY; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NADPH OXIDASE; PROGNOSIS; RISK; ROC CURVE; YOUNG ADULT;

EID: 84964896161     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4745     Document Type: Article

References (26)

1. Yang JD and Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7: 448-458, 2010.
2. Sakamoto M: Early HCC: Diagnosis and molecular markers. J Gastroenterol 44 (Suppl 19): 108-111, 2009.
3. Roy K, Wu Y, Meitzler JL, Juhasz A, Liu H, Jiang G, Lu J, Antony S and Doroshow JH: NADPH oxidases and cancer. Clin Sci (Lond) 128: 863-875, 2015.
4. De Deken X, Wang D, Many MC, Costagliola S, Libert F, Vassart G, Dumont JE and Miot F: Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem 275: 23227-23233, 2000.
5. Fischer H: Mechanisms and function of DUOX in epithelia of the lung. Antioxid Redox Signal 11: 2453-2465, 2009.
6. Luxen S, Belinsky SA and Knaus UG: Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res 68: 1037-1045, 2008.
7. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F and Schlumberger M: Poorly differentiated follicular thyroid carcinoma: Prognostic factors and relevance of histological classification. Thyroid 17: 639-646, 2007.
8. Ling Q, Shi W, Huang C, Zheng J, Cheng Q, Yu K, Chen S, Zhang H, Li N and Chen M: Epigenetic silencing of dual oxidase 1 by promoter hypermethylation in human hepatocellular carcinoma. Am J Cancer Res 4: 508-517, 2014.
9. Tong L, Chuang CC, Wu S and Zuo L: Reactive oxygen species in redox cancer therapy. Cancer Lett 367: 18-25, 2015.
10. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE and Chumakov PM: The antioxidant function of the p53 tumor suppressor. Nat Med 11: 1306-1313, 2005.
11. D'Autréaux B and Toledano MB: ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8: 813-824, 2007.
12. Bhattacharyya S and Saha J: Tumour, oxidative stress and host t cell response: Cementing the dominance. Scand J Immunol 82: 477-488, 2015.
13. Cabello CM, Bair WB III and Wondrak GT: Experimental therapeutics: Targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs 8: 1022-1037, 2007.
14. Fruehauf JP and Meyskens FL Jr: Reactive oxygen species: A breath of life or death? Clin Cancer Res 13: 789-794, 2007.
15. Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M, Kimoto T, Takemoto Y, Nakamura T and Yukaya H: Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 217: 375-384, 1993.
16. Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real- Time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25: 402-408, 2001.
19. Gokcan H, Savas N, Oztuna D, Moray G, Boyvat F and Haberal M: Predictors of survival in hepatocellular carcinoma patients. Ann Transplant 20: 596-603, 2015.
20. Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH and Lee SG: The impact of tumor size on long- Term survival outcomes after resection of solitary hepatocellular carcinoma: Single-institution experience with 2558 patients. J Gastrointest Surg 19: 1281-1290, 2015.
21. Nickel A, Kohlhaas M and Maack C: Mitochondrial reactive oxygen species production and elimination. J Mol Cell Cardiol 73: 26-33, 2014.
22. Ramsey MR and Sharpless NE: ROS as a tumour suppressor? Nat Cell Biol 8: 1213-1215, 2006.
23. Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan MC and Linder S: Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 120: 175-180, 2007.
24. Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815, 2001.
25. Kao WY, Chao Y, Chang CC, Li CP, Su CW, Huo TI, Huang YH, Chang YJ, Lin HC and Wu JC: Prognosis of early-stage hepatocellular carcinoma: The clinical implications of substages of Barcelona Clinic Liver Cancer System based on a cohort of 1265 patients. Medicine (Baltimore) 94: E1929, 2015.
26. Hahn WC and Weinberg RA: Rules for making human tumor cells. N Engl J Med 347: 1593-1603, 2002.